NeoALTTO trial results

Zoledronic acid disappointment for early breast cancer

Next generation gene sequencing

Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer

CTCs predict poor outcome from blood stem cell transplantation therapy for metastatic breast cancer

Denosumab delayed first skeletal-related side effect

High CTC levels predicted poor outcome in metastatic breast cancer

CTCs predicted recurrence and death in patients with early-stage breast cancer

Combination therapy reduced HER2-positive breast cancers

Neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer

Union for International Cancer Control: successes and the future

Computational modelling of signalling pathways